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Abstract
Background: In addition to single-locus (main) effects of disease variants, there is a growing
consensus that gene-gene and gene-environment interactions may play important roles in disease
etiology. However, for the very large numbers of genetic markers currently in use, it has proven
difficult to develop suitable and efficient approaches for detecting effects other than main effects
due to single variants.
Results: We developed a method for jointly detecting disease-causing single-locus effects and
gene-gene interactions. Our method is based on finding differences of genotype pattern frequencies
between case and control individuals. Those single-nucleotide polymorphism markers with largest
single-locus association test statistics are included in a pattern. For a logistic regression model
comprising three disease variants exerting main and epistatic interaction effects, we demonstrate
that our method is vastly superior to the traditional approach of looking for single-locus effects. In
addition, our method is suitable for estimating the number of disease variants in a dataset. We
successfully apply our approach to data on Parkinson Disease and heroin addiction.
Conclusion: Our approach is suitable and powerful for detecting disease susceptibility variants
with potentially small main effects and strong interaction effects. It can be applied to large numbers
of genetic markers.
Background
It is now generally accepted that complex genetic traits
such as diabetes and schizophrenia are under the influ-
ence of multiple interacting loci and environmental trig-
gers, each with a possibly small effect. Thus, to overcome
the limitations of traditional single-locus association
analysis (looking for main effects of single marker loci),
various methods have been developed to investigate the
joint disease association of multiple markers. As an
approximation to multivariate analysis [1], sums of sin-
gle-locus association statistics [2] have proven to be effi-
cient, powerful [3], and applicable to large numbers of
markers. A more direct approach is to investigate whether
sets of specific alleles or genotypes at different loci occur
more frequently in case than control individuals [4,5].
from The Seventh Asia Pacific Bioinformatics Conference (APBC 2009)
Beijing, China. 13–16 January 2009
Published: 30 January 2009
BMC Bioinformatics 2009, 10(Suppl 1):S75 doi:10.1186/1471-2105-10-S1-S75
<supplement> <title> <p>Selected papers from the Seventh Asia-Pacific Bioinformatics Conference (APBC 2009)</p> </title> <editor>Michael Q Zhang, Michael S Waterman and Xuegong Zhang</editor> <note>Research</note> </supplement>
This article is available from: http://www.biomedcentral.com/1471-2105/10/S1/S75
© 2009 Long et al; licensee BioMed Central Ltd. 
This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Bioinformatics 2009, 10(Suppl 1):S75 http://www.biomedcentral.com/1471-2105/10/S1/S75
Page 2 of 6
(page number not for citation purposes)
Haplotypes are sets of alleles, one each at different loci, on
a chromosome. Each individual has two haplotypes but,
because of unknown phase, it is generally not possible to
identify the two specific haplotypes in a given individual.
For this reason, we prefer to work with sets of genotypes at
different loci (diplotypes). To allow for possible interac-
tions between any genes, we consider genotypes at differ-
ent loci, wherever these occur in the genome, and refer to
such sets of genotypes as genotype patterns.
The simplest situation to consider is that of two genetic
markers. Throughout this paper we will focus on single
nucleotide polymorphisms (SNPs). One pair of SNPs,
each with 3 genotypes, comprises a maximum of 9 geno-
type patterns. A possible strategy is to investigate all pairs
of SNPs to see for each pair whether the genotype pattern
frequencies are different in case and control individuals
[6]. Several diseases have been described requiring a
mutation at two different loci while occurrence of a muta-
tion at only one locus does not lead to disease [7].
At least in experimental organisms, researchers have
developed methods to specifically search for epistatic
interactions between two loci, with the aim to detect net-
works of interacting loci [8]. In human genetics, several
approaches to detecting the joint effects of multiple sus-
ceptibility variants have been proposed [9-14]. However,
many of these methods are applicable only to small num-
bers of SNPs and are not suitable for genome-wide analy-
sis of 100,000s of markers. For this reason, two-step
approaches are more promising [2,15,16]. Specifically, for
two-locus disease models, a two-step approach has been
proposed that initially selects SNPs based on significant
single-locus tests, with logistic regression analysis of all
possible main and interaction effects at the second stage
[16]. Here, we proceed in a similar manner but with
important differences: initial selection of SNPs is also car-
ried out based on their single-locus test results but irre-
spective of whether these are significant, and the number
of these test SNPs to be carried forward for second-stage
analysis may be varied from 1 up to any desired maxi-
mum number, m, limited only by computer resources.
Instead of logistic regression analysis, we propose to test
whether for a given number m of test SNPs the frequencies
of genotype patterns is different in case and control indi-
viduals.
It should be noted that genotype pattern frequencies com-
prise main effects (at one or multiple loci) and epistatic
interaction effects. Here our focus is on genotype patterns
with an interest in finding pattern frequencies reflecting a
high degree of epistatic interaction so that disease-associ-
ated SNPs may be found even though they contribute to
disease more through interaction effects than direct main
effects. Such genes have been found, for example, in bar-
ley [17], and so-called digenic traits are known in humans
[7].
Methods
Pattern recognition approach
Consider a dataset with a certain number of case and con-
trol individuals, each genotyped at a number M of SNPs,
where M might be equal to 1 million, say. We want to find
disease-associated patterns of m SNPs, m <<M, each pat-
tern consisting of a genotype at each of the m SNPs. The
total number of subsets of m SNPs that can be formed
from M SNPs is equal to M!/[m!(M - m)!], and each of
these subsets contains a maximum of 3m genotype pat-
terns. Thus, searching through all possible patterns of
even a small number m of SNPs is an enormous task and
generally too computationally intensive. One might con-
sider picking a random sample of all possible genotype
patterns and evaluate them for association with disease,
that is, testing whether pattern frequencies are signifi-
cantly different between case and control individuals. A
more satisfactory solution seems to select patterns with
certain desirable properties, for example, patterns formed
of SNPs that have been suitably prioritized [18]. In the
absence of biological and sequence-based information,
the statistically most relevant prioritization is based on
the significance level (p-value) achieved in an association
test. In other words, we select SNPs having the largest
main effects. Presumably, epistatic interaction as a disease
causing mechanism will also result in some main effects
although these are not necessarily significant. Such main
effects are at least predicted under logistic regression mod-
els (see below). We propose the following two-step
approach.
Pattern test
(1) For each of a possibly very large number M of SNPs,
an association test is carried out, for example, chi-square
is computed for a 2 × 3 contingency table of genotypes,
where the two rows correspond to cases and controls, and
columns refer to the three SNP genotypes. The top m SNPs
(with largest chi-square) are singled out for further analy-
sis, where m may be guided by considerations such as
potential importance for disease of the genes containing
these SNPs. (2) For the selected m test SNPs, all genotype
patterns are identified and their frequencies established.
Those patterns with frequencies below 5% in cases and
controls each are pooled into a "rare" class. For example,
with m = 3, the total number of genotype patterns is 27.
Some patterns may not occur in the given data and rare
patterns are pooled into a single class so that only r pat-
terns with appreciable frequency are observed. These data
are now arranged in a 2 × r contingency table, for which
chi-square and an associated significance level, pm, is com-
puted.BMC Bioinformatics 2009, 10(Suppl 1):S75 http://www.biomedcentral.com/1471-2105/10/S1/S75
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We take pm as our experiment-wise test statistic (rather
than chi-square, which may have different degrees of free-
dom depending on the number s of genotype patterns).
Clearly, pm may not be taken at face value as a significance
level – the type 1 error would be grossly inflated because
pm is based on the ascertainment of the m best SNPs. Thus,
we need to establish the significance level associated with
our observed value of pm, that is, determine the probabil-
ity of obtaining a value as small or smaller than the one
observed without there being an association (null hypoth-
esis). We do this in N randomization samples, that is, we
randomly permute the labels "case" and "control" and
leave everything else intact. In each randomization sam-
ple, the top m SNPs are determined, wherever they occur
in the genome, and p'm is computed in analogy to pm in
the observed dataset. A large number of randomization
samples will then furnish an approximate null distribu-
tion for pm, from which the significance level is obtained
as the proportion of randomization samples with p'm = pm.
Unless noted otherwise, our calculations are carried out
with N = 50,000 randomization samples. We compare
our pattern test with the following conventional SNP-by-
SNP approach.
Single-locus test
For each of the m best SNPs we compute chi-square for a
2 × 3 contingency table, with rows corresponding to cases/
controls and columns representing the three SNP geno-
types. Significance levels associated with each of the m
SNPs are again evaluated in randomization samples. That
is, for each observed chi-square the proportion of rand-
omization samples is determined in which a chi-square as
large or larger than the one observed occurs. In other
words, the reference (null) distribution is that of the larg-
est chi-square [1].
Disease model and power calculations
To evaluate whether our pattern test does better than the
single-locus test, we carry out power calculations by gen-
erating case and control individuals under a suitable dis-
ease inheritance model. Because of its flexibility, we apply
a logistic regression model [19] as follows. We assume md
= 3 disease loci, each with two equally frequent alleles A
and B. At the i-th disease locus, we assign a code xi = -1 to
genotypes AA and AB, and a code xi = +1 to genotype BB.
Thus, genotype codes of -1 and +1 have associated respec-
tive probabilities of occurrence of 0.75 and 0.25. Then the
logistic disease model is given by
log [f/(1 - f)] = a0 + a1(x1 + x2 + x3) + a2(x1x2 + x1x3 + x2x3) 
+ a3x1x2x3 = s,
where f is the conditional probability of being affected
given the genotype pattern specified by the xi's (f is often
called penetrance) and the ai are coefficients representing
main (a1) and interaction effects (a2, a3). For simplicity,
all main effects are the same and all first-order (pairwise)
interaction effects are the same, while a1 = a2 = a3 = 0 cor-
responds to the null hypothesis of no genetic effects. For
any setting of ai > 0 (i > 0), the parameter a0 is chosen in
such a way that the model predicts a disease prevalence of
K  = 0.05. For example, this prevalence is predicted by
parameter values a1 = a2 = 0, a3 = 3, and a0 = -5.05. Note
that such a model containing only a second-order interac-
tion effect does induce some direct genotype effects at
each of the three disease loci. Depending on the genotype
pattern, these parameter settings lead to odds ratios (ORs)
for disease ranging from 0.0034 through 3.12 and, at each
single locus, lead to ORs of 0.58 and 1.71 for the respec-
tive genotype codes xi = -1 and xi = +1.
Initially, we only consider md = 3 SNPs in complete asso-
ciation with disease susceptibility variants. This way we
directly compare power between the pattern and single-
locus tests. Subsequently we also consider the effects of
unassociated SNPs and how they degrade power.
Results
Simulation with disease SNPs
Power calculations in this section were carried out for
sample sizes of 50 case and control individuals each. For
a pure main-effects model (a1 > 0, a2 = a3 = 0), Figure 1
shows that pattern and single-locus approaches have vir-
tually the same power. This is to be expected: Disease
SNPs are assumed uncorrelated and each acts independ-
ently. On the other hand, in the presence of second-order
interaction effects (a1 = a2 = 0, a3 > 0), with direct single-
locus effects only present inasmuch as they are induced by
interaction effects (see above), Figure 2 demonstrates the
Power (Y-Axis) as a function of main effects (x-axis) Figure 1
Power (Y-axis) as a function of main effects (x-axis). 
For a pure main-effects model (x-axis = a1 > 0; interaction 
effects a2 = a3 = 0 are all zero), Figure 1 shows that pattern 
(solid red line) and single-locus (broken blue line) approaches 
have virtually the same power.BMC Bioinformatics 2009, 10(Suppl 1):S75 http://www.biomedcentral.com/1471-2105/10/S1/S75
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tremendous power advantage of the pattern approach
over the single-locus approach.
Simulation with disease and unassociated SNPs
With  md susceptibility SNPs and M  unassociated SNPs
(total of md + M SNPs), we need to define "success" in our
simulations. In a given randomization sample, it is no
longer sufficient that p'm = pm. In addition, we require that
the particular subset of m = 3 ascertained SNPs with high-
est chi-square values comprise at least one disease SNP.
An analogous rule applies to the single-locus test.
For 100 case and controls each, with a1 = 1, a2 = 0, and a3
= 6, Figure 3 shows the deleterious effects of "noise" SNPs.
In the presence of M = 1500 unassociated SNPs, power
drops from 100% to 20%, where power loss is somewhat
smaller for the pattern than the single-locus approach
although both suffer greatly. This power loss may be offset
by using additional observations. With the same parame-
ter values, to maintain a power of 80%, Figure 4 shows
that for the pattern method an increase in sample size
from 100 to 180 is sufficient to offset the harmful effects
of "noise" SNPs. As the number of unassociated SNPs
increases, required sample sizes initially increase strongly
but later less so. The required sample size increase is virtu-
ally the same for the two association tests considered here
so that only one curve is shown in Figure 4.
Choice of number Of SNPs for analysis
So far, we analyzed data looking for patterns of length m
= 3 while the data were generated with md = 3. In reality,
of course, the number md of disease variants is unknown.
Thus, for our epistatic disease model (a1 = a2 = 0, a3 > 0, md
= 3, no other SNPs, 100 cases and controls each), we esti-
mated power for different numbers m of best SNPs con-
sidered. Not unexpectedly, power is highest when m = md
(Figure 5). Also, power is better when m > md then when
m  <md. As highest power is expected to translate into
smallest p-value, trying different numbers m of SNPs is
expected to estimate the number of disease variants in a
dataset.
Sample sizes (numbers of cases and controls, y-axis) for  power of 80% Figure 4
Sample sizes (numbers of cases and controls, y-axis) 
for power of 80%. The power loss due to increasing num-
bers M of unassociated SNPs may be offset by increased sam-
ple sizes. Figure 4 shows the numbers of cases and controls 
each (y-axis) that are necessary to maintain power of 80% in 
the presence of M of unassociated SNPs (x-axis). Parameter 
values are as in Figure 3. Pattern approach (solid red line) and 
single-locus approach (broken blue line) furnish virtually 
identical results.
Power (y-axis) as a function of interaction effects (x-axis) Figure 2
Power (y-axis) as a function of interaction effects (x-
axis). With strong second order interaction effects (x-axis = 
a3; a1 = a2 = 0), the pattern approach (solid red line) is much 
more powerful than the single-locus test (broken blue line).
Power (y-axis) as a function of the total number, M, of SNPs Figure 3
Power (y-axis) as a function of the total number, M, 
of SNPs. Figure 3 shows that power is strongly reduced by 
the presence of random (unassociated) markers. For 100 
cases and controls each, under a model with main and inter-
action effects (a1 = 1, a2 = 0, a3 = 6), pattern approach (solid 
red line) and single-locus approach (broken blue line) suffer 
approximately the same power losses.BMC Bioinformatics 2009, 10(Suppl 1):S75 http://www.biomedcentral.com/1471-2105/10/S1/S75
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Analysis of Parkinson's Disease dataset
A dataset with approximately 540 case and control indi-
viduals and approximately 408,000 SNPs genome-wide is
available for re-analysis [20]. For our purpose, we chose to
work with the 19,494 SNPs on chromosome 11 that
passed our quality control measures; SNP rs10501570 on
that chromosome was previously associated with Parkin-
son's Disease (PD) [20]. We decided to work with a subset
size of m = 3 SNPs. In chi-square tests for 2 × 3 tables
(case/control phenotype versus three SNP genotypes), the
three largest values occurred for SNPs rs12364577,
rs1377470, and rs10501570. In 10,000 randomization
samples, the largest chi-square had an associated signifi-
cance level of 5/10,000 = 0.0005 (corrected for multiple
testing) while the other two chi-square values had associ-
ated p-values of 0.0023 and 0.0030. Forming genotype
patterns for these three SNPs, we found five patterns with
frequencies of at least 0.05 in either case or control indi-
viduals; the remaining patterns were combined into a
"rare" class. The chi-square for the resulting 2 × 6 table
had an associated randomized significance level of
0.0064. Evidently, for this dataset the single-locus test was
more effective than our pattern test (0.0005 < 0.0064),
presumably because of strong single-locus effects.
Analysis of a dataset for heroin addiction
In 104 former severe heroin addicts and 101 control indi-
viduals (all Caucasians), a case-control association analy-
sis was carried with 10,000 SNPs [21]. Single-locus
analysis furnished nonsignificant results: The largest chi-
square in 2 × 3 tables of genotypes had an associated p-
value of 0.15 (obtained in 10,000 randomization sam-
ples). On the other hand, evaluating genotype patterns for
the three SNPs with individually smallest p-values
revealed five common patterns, and the resulting 2 × 6
table of pattern frequencies had an associated experiment-
wise significance level of 0.026. As reported in [21], a spe-
cific genotype pattern was associated with heroin addic-
tion with an odds ratio of 6.25 while none of the
component SNPs by themselves were significantly dis-
ease-associated. Interestingly, when we investigated geno-
type patterns comprising two, four, or five SNPs, the
significance levels associated with the corresponding pat-
tern tables were all in excess of 0.30. Thus, the specific set
of three genetic variants identified seems to predispose to
disease [21].
Discussion
We report here a new multi-locus method for genetic case-
control association analysis that jointly evaluates main
and interaction effects of multiple genetic variants. In con-
trast to our Set Association method developed previously
[2], it is not based on main effects of individuals SNPs
only. Our method is able to find epistatic interaction
effects although the test SNPs chosen for analysis are
determined by SNP-specific association statistics. Clearly,
if SNPs have weak individual effects then they are unlikely
to be picked up by our approach. In an application to a
study of former heroin addicts, our genotype pattern
method clearly showed its advantages over standard sin-
gle-locus methods.
We implemented our approach in a computer program,
RandomPat, which is available on request and will soon be
available for downloading from our website [22].
In its current implementation, our method has a short-
coming in that it cannot handle missing observations.
Thus, for m SNPs it will ignore patterns that contain one
or more missing genotypes.
A major advantage of our approach is that the number, m,
of test SNPs can be chosen by the investigator. Varying m
from 1 up to a suitable upper limit will show, which
number of test SNPs is most significant in a given dataset.
As demonstrated in the previous section, such an
approach is expected to estimate the number of disease
variants if they are all of equal strengths.
Conclusion
As we demonstrated, our method is clearly superior to the
traditional approach of looking for single-locus effects. In
addition, it is suitable for estimating the number of dis-
ease variants in a dataset. On the other hand, purely epi-
static loci (no main effects by themselves) cannot be
detected by our approach.
Power (y-axis) of interaction effects (x-axis) for different  numbers of test SNPs Figure 5
Power (y-axis) of interaction effects (x-axis) for dif-
ferent numbers of test SNPs. For an epistatic disease 
model (a1 = a2 = 0, a3 > 0) with three disease SNPs, md = 3 
(no other SNPs, 100 cases and controls each), power (y-axis) 
is displayed as a function of the interaction coefficient, a3 (x-
axis), for different numbers m of test SNPs. Power is highest 
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